BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 21, Truist Securities initiated coverage of BBIO with a Buy rating and a $66 price target, spotlighting the promising launch of Attruby for treating ATTR-CM.
A closeup of a medical technician handling a sample of a biopharmaceutical drug.
Citing its growing use as a first-line therapy due to ease of access and better stabilizer data, Truist sees strong traction among tafamidis-progressing patients.
With the ATTR-CM market expected to reach $20 billion, Truist views significant upside for Attruby despite ongoing patent litigation from Pfizer. The firm remains optimistic about BridgeBio’s IP position and also highlighted near-term growth catalysts from its late-stage pipeline, particularly starting in the second half of 2025.
BridgeBio Pharma Inc. is a biopharmaceutical company that develops and delivers transformative medicines for genetic diseases and cancers with clear genetic drivers. It boasts a pipeline of candidate drugs, some in early-stage research and others in advanced clinical trials.
READ NEXT: 12 Best Airline Stocks to Buy According to Hedge Funds and Goldman Sachs REIT Stocks: Top 12 Stock Picks.
This article is originally published at Insider Monkey.
